Product Description
Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria. (Sourced from: https://www.nejm.org/doi/full/10.1056/nejmoa1310422)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Jordan | Latvia | Lithuania | Poland | Portugal | Saudi Arabia | Slovakia | Spain | Sweden | Switzerland | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Melinta
Company Location: MORRISTOWN NJ 07963
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, Greece, Latvia, Lithuania, Poland, Portugal, Romania, Spain, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Skin Diseases, Bacterial
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ML-ORI-201 | P2 |
Recruiting |
Skin Diseases, Bacterial |
2025-06-15 |
12% |
2024-02-21 |
Primary Endpoints|Study Completion Date|Treatments |
| ML-ORI-201 | P2 |
Not yet recruiting |
Unknown |
2025-06-30 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/02/2024 |
News Article |
Melinta Joins NHIA Future of Infusion Advisory Council |
|
10/16/2024 |
News Article |
Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta's Portfolio of Commercial and Investigational Stage Products |
|
09/05/2024 |
News Article |
Melinta Therapeutics Announces the Appointment of Sunitha Lakshminarayanan, as Chief Technology Officer |
|
08/06/2024 |
News Article |
Melinta Therapeutics Announces the Appointment of Fabrizio Tondolo, MD, as Vice President of Medical Affairs |